Rubiadin

Synonyms: 茜草素
Rubiadin 是一种具有口服活性的自由基清除剂,可抑制 NF-κB 通路的激活,并能抑制破骨细胞形成、骨吸收、脂质过氧化、HBV DNA 复制及癌细胞增殖,降低促炎细胞因子水平,诱导癌细胞凋亡 (apoptosis),且具有抗真菌、抗疟、抗菌和抗惊厥活性,可用于骨质疏松症、急性炎症、慢性炎症、四氯化碳诱导的肝损伤、阿尔茨海默病、乳腺癌、铁过载疾病、乙型肝炎病毒感染、结肠癌、肝癌、T 淋巴细胞白血病、宫颈癌、糖尿病肾病、癫痫发作、真菌感染、疟疾及细菌感染的研究。
产品编号: MS-V01156 纯度: 99.20% CAS No.: 117-02-2 分子式: C15H10O4 分子量: 254.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Rubiadin 是一种具有口服活性的自由基清除剂,可抑制 NF-κB 通路的激活,并能抑制破骨细胞形成、骨吸收、脂质过氧化、HBV DNA 复制及癌细胞增殖,降低促炎细胞因子水平,诱导癌细胞凋亡 (apoptosis),且具有抗真菌、抗疟、抗菌和抗惊厥活性,可用于骨质疏松症、急性炎症、慢性炎症、四氯化碳诱导的肝损伤、阿尔茨海默病、乳腺癌、铁过载疾病、乙型肝炎病毒感染、结肠癌、肝癌、T 淋巴细胞白血病、宫颈癌、糖尿病肾病、癫痫发作、真菌感染、疟疾及细菌感染的研究。

生物实验数据

生物活性 Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway and suppresses osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication, and cancer cell proliferation, reduces pro-inflammatory cytokine levels, induces cancer cell apoptosis (apoptosis), and exhibits antifungal, antimalarial, antibacterial, and anticonvulsant activities, and it can be used in research on osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload diseases, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria, and bacterial infections.
体外研究
(In Vitro)

Rubiadin (5-20 μM;预孵育 3 h,随后继续孵育 24 h) 可保护 N2a 细胞免受 Aβ1₋42 诱导的细胞毒性,与仅经 Aβ1₋42 处理的细胞相比,能显著提高细胞活力。
Rubiadin (5-20 μM;预孵育 3 h,随后继续孵育 24 h) 通过降低关键通路组分的磷酸化水平,抑制 Aβ1-42 诱导的 N2a 细胞中 IKK/IκB/NF-κB 通路的激活。
Rubiadin (1-100 μM;辐照后 24 h) 可在 MCF-7c3 人乳腺癌细胞中诱导具有光剂量依赖性的细胞毒性,其 LD50 为 0.66 J/cm2;在 100 μM 和 1 J/cm2 的条件下,细胞存活率降低 76%。
Rubiadin (0.4-40 μM;24 h) 不会损害人 HepG2 细胞的活力。
Rubiadin (0.4-40 μM;24 h,呈剂量依赖性) 及 Rubiadin (20 μM;3-24 h,呈时间依赖性) 可在人 HepG2 细胞中以剂量依赖和时间依赖的方式上调 hepcidin mRNA 及蛋白的表达,在 20 μM 处理 24 h 时 mRNA 上调幅度达到最高 5 倍。
Rubiadin (5、10、20、40 μg/ml;作用 72 h) 可呈剂量依赖性抑制 HepG2.2.15 细胞的增殖,其 IC50 为 17 μg/ml,且非毒性浓度 (<8 μg/ml) 的特性支持将其用于抗 HBV 活性实验。
Rubiadin (4、6 μg/ml;24、48、72 h) 可剂量依赖性地降低 HepG2.2.15 细胞的 HBsAg、HBeAg 及 HBcAg 分泌水平,且在 72 h 时对 HBeAg 和 HBcAg 的抑制作用尤为显著。
Rubiadin 可抑制热带假丝酵母菌(Candida tropicalis) 生物膜的形成,并在辐照条件下诱导氧化应激,还能与两性霉素 B (Amphotericin B) 协同作用于该真菌。
Rubiadin 可抑制恶性疟原虫 (Plasmodium falciparum) 的活性,其 IC50 为 13.00 μg/mL,并以剂量依赖的方式减少裂殖体数量。
Rubiadin 在水性生理介质 (pH 7.4) 中表现出中等强度的实验性 DPPH 自由基清除活性,其 IC50 为 91.00 μM。
Rubiadin 在生理水性介质 (pH 7.4) 中表现出中等强度的实验性 ABTS•+ 自由基清除活性,其 IC50 为 73.44 μM。

Cell Viability Assay

Cell Line: mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration: 5 μM; 20 μM
Incubation Time: 3 h pre-incubation, then 24 h continued incubation
Result: Significantly improved cell viability in Aβ1₋42-exposed N2a cells.

Western Blot Analysis

Cell Line: mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration: 5 μM; 20 μM
Incubation Time: 3 h pre-incubation, then 24 h continued incubation
Result: Reduced the expression levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α. Increased the expression of anti-inflammatory cytokine IL-4. Decreased phosphorylated Tau protein expression in Aβ1₋42-exposed N2a cells.\nSignificantly inhibited the phosphorylation of IKK, IκB, and NF-κB in Aβ1₋42-exposed N2a cells.

Immunofluorescence

Cell Line: mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration: 5 μM; 20 μM
Incubation Time: 3 h pre-incubation, then 24 h continued incubation
Result: Reversed the increased nuclear overlap of NF-κB and DAPI-labeled nuclei observed in Aβ1₋42-exposed N2a cells. Significantly reduced NF-κB nuclear fluorescence intensity.

Cell Cytotoxicity Assay

Cell Line: MCF-7c3 human breast cancer cells
Concentration: 1, 50, 100 μM
Incubation Time: 24 h (post-irradiation)
Result: Exhibited photochemical activity in a light dose-dependent manner, with an LD50 value at 0.66 J/cm2 light dose and 76% cell killing at 1 J/cm2.

Western Blot Analysis

Cell Line: human HepG2 cells, ferric ammonium citrate (FAC)-treated human HepG2 cells
Concentration: 0.4, 4, 8, 20, 40 μM (untreated cells); 20 μM (FAC-pretreated cells)
Incubation Time: 24 h (untreated cells); 24 h (FAC-pretreated cells)
Result: Dose-dependently decreased protein expression of TfR1, Fpn1 and FtL in untreated HepG2 cells, with significant reductions at 20 and 40 μM for TfR1 and Fpn1, and at 8, 20, and 40 μM for FtL; had no significant effect on divalen DMT1 or FtH expression.\nFurther decreased TfR1 protein expression and reversed FAC-induced elevation of FtL protein expression in FAC-pretreated HepG2 cells; had no significant effect on Fpn1, DMT1, or FtH expression in FAC-pretreated cells.

ELISA Assay

Cell Line: HepG2.2.15 human hepatoma cells
Concentration: 4, 6 μg/ml
Incubation Time: 24, 48, 72 h
Result: Dose-dependently decreased extracellular levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antigen (HBcAg). Reduced HBeAg secretion by 26.31% and HBcAg secretion by 29.26% at 72 h, with more efficient inhibition than the positive control.

Cell Cycle Analysis

Cell Line: HepG2.2.15 human hepatoma cells
Concentration: 4, 6 μg/ml
Incubation Time: 72 h
Result: Resulted in G0/G1 phase percentages of 75.2% (4 μg/ml) and 78.1% (6 μg/ml), with no statistically significant difference from the untreated control (73.3%). Induced no cell cycle arrest.
体内研究
(In Vivo)

Rubiadin (0.3-0.5 mg/kg; i.p.; single dose) 具有显著的急性抗炎活性,在雄性 Wistar 白化大鼠中可对角叉菜胶诱导的足爪水肿峰值产生 61%的抑制作用,并显著降低足爪组织中的 TNF-α 水平。
Rubiadin (50-200 mg/kg;灌胃;每日给药;连续 14 天) 对 Sprague-Dawley 大鼠中 CCl4 诱导的肝损伤表现出剂量依赖性的保肝活性,其中 100 和 200 mg/kg 剂量下的疗效具有极显著性,接近阳性对照药物水飞蓟素的活性。
Rubiadin (20 mg/kg; 灌胃给药; 每日 1 次; 连续 8 周) 可改善 APP/PS1 阿尔茨海默病模型小鼠的空间与非空间记忆,减少大脑 Aβ 沉积,缓解神经炎症,并抑制 NF-κB 通路的激活。
Rubiadin (1 mg/kg;腹腔注射;每隔 1 天给药;持续 6 周) 可降低 8 周龄正常雄性 C57BL/6 小鼠的血清铁、总铁结合力及转铁蛋白饱和度。
Rubiadin (5-20 mg/kg; i.p.; 每日;连续 4 周) 可通过逆转脾肿大、降低血清铁参数及十二指肠铁含量、增强肝脏 hepcidin 表达与 SMAD1/5/9 磷酸化,缓解高铁饮食喂养的 C57BL/6 雄性小鼠的铁过载状态。
Rubiadin (100-250 mg/kg;灌胃;每日 1 次;连续 3 天) 对 Swiss albino mice(瑞士白化小鼠) 具有抗惊厥作用,当以 100 和 250 mg/kg 剂量灌胃给药 3 天时,可降低戊四唑模型和最大电休克模型中的癫痫发作严重程度。
Rubiadin (0.04%;膳食性;每日给药;持续 23 周) 是作用于 F344 大鼠的致癌代谢物,当以膳食中 0.04%的剂量给药 23 周时,会促进肾肿瘤前病变、肝细胞灶和肠道发育异常。

Animal Model: Wistar albino rats (male, 150-200 g)
Dosage: 0.3 mg/kg; 0.5 mg/kg
Administration: i.p.; single dose
Result: Produced paw edema inhibition percentages of 24% (0.5 hr), 17.5% (1 hr), 8.3% (2 hr), 21% (3 hr), and 13% (4 hr) at 0.3 mg/kg.\nProduced paw edema inhibition percentages of 48% (0.5 hr), 40% (1 hr), 45% (2 hr), 61% (3 hr), and 54% (4 hr) at 0.5 mg/kg, with 61% inhibition at peak edema time being statistically significant.\nCaused a statistically significant decrease in paw tissue TNF-α levels at 0.5 mg/kg compared to controls.\nSignificantly reduced paw tissue edema and histopathological damage compared to controls at both doses.
Animal Model: Wistar albino rats (male, 150-200 g)
Dosage: 0.3 mg/kg; 0.5 mg/kg
Administration: i.p.; daily; 7 days
Result: Produced 34.71% inhibition of granuloma formation and 19.76% inhibition of transudate formation at 0.3 mg/kg.\nProduced 46.12% inhibition of granuloma formation and 38.13% inhibition of transudate formation at 0.5 mg/kg, with both values statistically. Caused a statistically significant decrease in serum IL-1β levels at 0.5 mg/kg compared to controls.
Animal Model: C57BL/6 (6-week-old, male; high-iron diet-induced iron overload)
Dosage: 5 mg/kg; 20 mg/kg
Administration: i.p.; daily; 4 weeks
Result: Did not significantly affect mouse body weight.\nSignificantly reversed splenomegaly, reduced elevated serum iron, total iron-binding capacity, and transferrin saturation caused by the high-iron diet, and reversed the elevated duodenal iron content caused by the high-iron diet.\nFurther increased hepatic hepcidin mRNA expression, hepatic hepcidin protein expression, and hepatic SMAD1/5/9 phosphorylation levels relative to the high-iron diet alone.
Animal Model: Wistar (carbon tetrachloride-induced liver injury)
Dosage: 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: p.o.; daily; 2 weeks
Result: Restored serum glutamic oxaloacetic transaminase, glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyltransferase, glutathione S-transferase, and glutathione reductase levels to normal.\nInhibited hepatic malondialdehyde formation in a dose-dependent manner.\nReduced glutathione depletion in a dose-dependent manner.
Animal Model: Wistar (streptozotocin-nicotinamide-induced diabetic nephropathy)
Dosage: 100 mg/kg/week; 200 mg/kg/week
Administration: p.o.
Result: Markedly reduced blood glucose levels, urea, uric acid, and creatinine levels.\nImproved lipid, thiobarbituric acid reactive substances, glutathione, superoxide dismutase, and catalase levels.
Animal Model: F344
Dosage: 0.04%
Administration: dietary; daily; 23 weeks
Result: Enhanced atypical renal tubules/hyperplasias.\nInduced renal cell adenomas and carcinomas.\nIncreased glutathione S-transferase placental form-positive liver cell foci.\nCaused major intestinal dysplasias.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 254.24
分子式 C15H10O4
CAS No. 117-02-2
别名 茜草素

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 6.25 mg/mL (24.58 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9333 mL19.6665 mL39.3329 mL98.3323 mL
5 mM0.7867 mL3.9333 mL7.8666 mL19.6665 mL
10 mM0.3933 mL1.9666 mL3.9333 mL9.8332 mL
15 mM0.2622 mL1.3111 mL2.6222 mL6.5555 mL
20 mM0.1967 mL0.9833 mL1.9666 mL4.9166 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础